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Nanotechnology has made a significant impact on the development of nanomedicine. Nonviral vectors have been
attracting more attention for the advantage of biosafety in gene delivery. Polyethylenimine (PEI)-conjugated chitosan
(chitosan-g-PEI) emerged as a promising nonviral vector and has been demonstrated in many tumor cells. However,
there is a lack of study focused on the behavior of this vector in stem cells which hold great potential in regenerative
medicine. Therefore, in this study, in vitro gene delivering effect of chitosan-g-PEI was investigated in bone marrow
stem cells. pIRES2-ZsGreen1-hBMP2 dual expression plasmid containing both the ZsGreen1 GFP reporter gene and the
BMP2 functional gene was constructed for monitoring the transgene expression level. Chitosan-g-PEI-mediated gene
transfer showed 17.2% of transfection efficiency and more than 80% of cell viability in stem cells. These values were
higher than that of PEI. The expression of the delivered BMP2 gene in stem cells enhanced the osteogenic differentiation.
These results demonstrated that chitosan-g-PEI is capable of applying in delivering gene to stem cells and providing
potential applications in stem cell-based gene therapy.
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Bone regeneration is one of the major focus points in
the field of regenerative medicine. Bone morphogenetic
protein-2 (BMP2) is a well-known stimulus for bone re-
generation [1]. Currently, nanotechnology has made a
significant impact on the development of drug delivery
system including the gene delivery [2]. This procedure
addresses some of the shortcomings associated with
BMP2 protein treatment such as the short half-life and
extremely high cost [3,4]. Gene therapy could not only
reduce the cost of the treatment but also prolong the re-
lease of BMP2 at the regeneration site to coincide with
bone formation [5,6].
The success of gene therapy depends on the develop-
ment of the efficient and safe gene delivery system. Viral
vectors are the preferred system in clinical trials due to* Correspondence: zhaoxltju@gmail.com
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in any medium, provided the original work is ptheir high transfection efficiency; however, the safety
concerns in terms of immune response and insertional
mutagenesis make the nonviral vectors more and more
attractive [7-9]. Nonviral vectors show the advantages in
easy manufacturing, low immune response, as well as
the unrestricted genetic material carrying capacity [9,10].
In clinical, the transient gene expression property of
nonviral vector can avoid the adverse effect of BMPs’
overexpression [11].
Among various nonviral vectors, cationic polymer has
emerged as a promising one for gene therapy. The struc-
tural flexibility of polymer allows for the variety of modi-
fication to fabricate a more powerful vector in terms of
efficacy and multifunction [12]. Chitosan, known for its
excellent biocompatibility and biodegradability, is one of
the most widely used cationic nonviral vectors [13]. How-
ever, its low transfection efficiency limits its application.
There is an increasing interest in improving chitosan’s
properties by various modifications. Polyethylenimine
(PEI) is another promising cationic nonviral vector and
has been proven as one of the most powerful and versatile
members of nonviral vector both in vitro and in vivo
[14,15]. However, this vector possesses relatively highOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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[16]. It has therefore not yet been used in human studies.
In recent years, many pilot studies had proven that the
combination of chitosan and PEI can simultaneously en-
hance the transfection efficiency and decrease the cyto-
toxicity [17-19]. This formula could be further improved
with the properties of targeted delivery [20-23], pro-
longed in vivo circulation [20], and stimuli-responsive
[24] by specific structure modification. However, most of
these studies were carried out in tumor cells such as
HeLa [20,24-26], HepG2 [27], and A549 cells [28], or
targeted for tumor treatment [21,29-31]. There are only
a few studies left using it to deliver gene to somatic cell
such as murine macrophage cells [22] and osteoarthritis
[32]. In our previous study, the bioreducible low mo-
lecular weight PEI-conjugated chitosan (chitosan-g-PEI)
was developed, characterized, and applied to deliver gene
to osteoblast cells [33]. It was also simply tried in stem
cells. However, there is a lack of a detailed study focused
on the behavior of this vector in stem cells, which is very
important in the regenerative medicine.
Vectors usually show the cell type-dependent transfec-
tion properties because of the differences in cell cycle,
cell division frequency, endocytic capacity, and meta-
bolic activity [34]. Mesenchymal stem cells (MSCs) are
usually more difficult to transfect [35]. In recent years,
the investigation of MSCs and their clinical application
have attracted extensive interests. Some nonviral vectors
have demonstrated their efficiency in delivering BMP2
gene to MSC such as liposome and PEI [36,37]. So far,
there are few nonviral vectors that have been applied in
stem cells, leaving very limited choices for stem cell-
based gene therapy. Therefore, chitosan-g-PEI should be
expected to show its effect on stem cells.
In this study, chitosan-g-PEI was evaluated on deliver-
ing BMP2 gene to bone marrow stem cells and com-
pared with chitosan and PEI in terms of the transfection
properties and the transgene function in vitro. pIRES2-
ZsGreen1-hBMP2 dual expression plasmid containing
both ZsGreen1 GFP reporter gene and BMP2 functional
gene was fabricated to monitor the transgene expression
level. The BMP2 expression in the transfected stem cells
was measured by the enzyme-linked immunosorbent
assay (ELISA) and Western blot. Alkaline phosphatase
(ALP) activity and Alizarin Red S staining were per-
formed to determine the osteogenic differentiation and
matrix mineralization.Methods
Materials
Chitosan (MW=10 kDa) with a 92% degree of deacetylation
was supplied by AK Biotech Ltd. (Jinan, Shandong, China).
Polyethylenimine (PEI,MW= 1.8 and 25 kDa) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) were purchased from Sigma-Aldrich (Shanghai,
China). N-Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP)
was provided by Thermo Scientific (Rockford, LA, USA).
PEI 25 kDa was purified by dialysis in deionized water and
lyophilization before used as positive control for gene de-
livery. Alizarin Red S, cetylpyridinium chloride (CPC), and
alkaline phosphatase (ALP) yellow liquid substrate were
obtained from Sigma. The BCA™ protein assay kit was ob-
tained from Thermo.
Construction of pIRES2-ZsGreen1-hBMP2 dual expression
vector
Plasmids pCI-neo-hBMP2 and pIRES2-ZsGreen1 (Clontech,
Mountain View, CA, USA) were maintained in the lab.
ZsGreen1 as GFP homolog is a bright green fluorescent
protein derived from a reef coral and modified for higher
solubility, brighter emission, and rapid chromophore mat-
uration. Plasmid pIRES2-ZsGreen1-hBMP2 was prepared
by inserting hBMP2 cDNA into pIRES2-ZsGreen1 plas-
mid at Xho I and BamH I sites using restriction enzyme
(TaKaRa, Otsu, Shiga, Japan) and T4 DNA ligase (NEW
ENGLAND BioLabs, Ipswich, MA, USA). hBMP2 cDNA
was amplified by PCR with the forward primer 5′- CCGctc
gagACCATGGTGGCCGGGACCCGCT-3′ and the reverse
primer 5′ -CGCggatccCTAGCGACACCCACAACCCTC
CA-3′ by KOD-Plus-Neo DNA polymerase (TOYOBO,
Osaka, Japan). Then, the product was transformed to
competent DH5α for amplification. Positive clones were
picked for mini plasmid preparation (QIAGEN, Hilden,
Germany). The recombinant plasmid pIRES2-ZsGreen1-
hBMP2 was characterized by PCR, restriction enzyme di-
gestion, and sequencing analysis, respectively. For cell
transfection, the plasmid was purified by Pure Yield™
Plasmid Midiprep System (Promega, Madison, WI, USA)
and then examined by gel electrophoresis and NanoDrop
ultraviolet spectrophotometer.
DNA complexes preparation
Chitosan-g-PEI was prepared according to the previous
study using SPDP heterobifunctional crosslinking re-
agent to conjugate chitosan (10 kDa) with PEI (1.8 kDa)
[33]. Briefly, SPDP was firstly reacted with the amino
group of chitosan and PEI, respectively, to prepare thio-
lated polymers. Then, chitosan-g-PEI was prepared by
oxidization of reduced thiols on PEI and chitosan at
room temperature in air to form a disulfide linkage. The
feed ratio of chitosan to PEI was 0.25:1 (w:w), in which
formula, it showed the optimal transfection properties in
our previous study [33]. Chitosan was purified and dis-
solved in 50 mM NaAc/HAc buffer (pH5.4). PEI 25 kDa
was dissolved in deionized water.
The DNA complexes were prepared freshly by adding
the equal volume of sterilized polymer solution to DNA
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at room temperature for 30 min for complexes formation.
The complexes of different vectors for gene transfer were
prepared at their optimal formula as 20:1, 20:1, and 2:1 for
chitosan, chitosan-g-PEI and PEI, respectively. Various
weight ratios of the complexes were prepared by manipu-
lating the concentration of polymer solutions. The critical
complex ratio was determined by gel electrophoresis.Complexes characterization
The DNA condensation ability was investigated by gel re-
tardation. Complex solutions contained 0.1 μg of DNA with
various weight ratios that were loaded into gels running at
90 V for 20 min. The particle size and surface charge of
complexes were measured by Zetasizer Nano ZS instru-
ment (Malvern Instruments, Malvern, Worcestershire, UK)
in triplicate at 25 °C. The complexes containing 2 μg of
DNA at various weight ratios (0.5:1 to 25:1) were diluted by
NaCl solution to 1 mL. The size was presented as the aver-
age value of five runs. The morphology of the complexes
was observed by transmission electron microscopy (TEM;
Philips Tecnai G2 20 S-TEM, Hillsboro, OR, USA). One
drop of each complex solution was carefully dropped on a
clean copper grid and negatively stained by 1.5 wt% phos-
photungstic acid (pH 6.7). The samples were dried at room
temperature before imaging.Cell culture
Murine bone marrow cells were collected by flushing
the bone marrow cavities of 6-week-old wild-type maleFigure 1 Construction and verification of pIRES2-ZsGreen1-hBMP2 plasmid
functional gene of BMP2 and the reporter gene of ZxGreen 1 GFP (A). COS
GFP expression observed under a fluorescence microscope (B) and the BMC57BL/6 mice euthanized by cervical dislocation and
then purified by its physical propensity of adherence to plas-
tic flasks [38]. The animal experiment and care were ap-
proved by the Institution Animal Care and Use Committee
(IACUC) of Shenzhen Institutes of Advanced Technology,
Chinese Academy of Sciences. Cells were cultured in
minimum essential medium (alpha) (α-MEM, Mediatech,
Herndon, VA, USA) supplemented with penicillin (Sigma-
Aldrich), streptomycin sulfate (Sigma-Aldrich), and 20%
fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville,
GA, USA) at 37 °C in a 5% CO2 humidified incubator. After
72 h of adhesion, nonadherent cells were removed and ad-
herent cells were cultured an additional 7 days with a single
media change. Cells were purified by flask adherence
through several passages. African green monkey kidney
cells (COS-1) were cultured in Dulbecco’s modified Eagle
medium (DMEM,Mediatech) supplemented with 10% fetal
bovine serum (FBS,Atlanta Biologicals). This cell was used
for confirmation of the construction of pIRES2-ZsGreen1-
hBMP2 plasmid.
In vitro differentiation of BMSC into multilineage cells
To assess the multilineage differentiation capacity, the
obtained bone marrow stem cells (BMSC) underwent
osteogenic, adipogenic, and chondrogenic induction by
different culture media.
For osteogenic differentiation, cells were cultured
with osteogenic medium with α-MEM supplemented
with 10% FBS, 10−7 M dexamethasone (Sigma-Aldrich),
10 mM β-glycerol phosphate (Sigma-Aldrich), and
50 mM ascorbate-2-phosphate (Sigma-Aldrich). AfterDNA. pIRES2-ZsGreen1-hBMP2 was constructed containing both the
-1 cells transfected with pIRES2-ZsGreen1-hBMP2 showed ZsGreen1
P2 mRNA expression by RT-PCR (C).
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stained by Alizarin Red S staining. For adipogenic dif-
ferentiation, cells were cultured with α-MEM supple-
mented with 10% FBS, 10−6 M dexamethasone, 0.5 μM
isobutylmethylxanthine (IBMX, Sigma-Aldrich), and
10 ng/mL of insulin (Sigma-Aldrich) for 2 weeks. Lipid
accumulation was identified by Oil Red O staining. For
chondrogenic differentiation, cells (1 × 106) were seeded
in polypropylene tubes with DMEM supplemented with
10−7 M dexamethasone, 1% insulin-transferrin-selenium
(ITS, Sigma-Aldrich), 50 μM ascorbate-2-phosphate,
1 mM sodium pyruvate (Sigma-Aldrich), 50 μg/mL of pro-
line (Sigma-Aldrich), and 20 ng/mL of TGF-β3 (R&D Sys-
tems, Minneapolis, MN, USA). After 3 weeks in culture,
the pellets were fixed in 10% buffered formalin for 48 h
and embedded in paraffin. Then, 4 μm thick sections were
processed for toluidine blue staining (Sigma-Aldrich).
Transfection efficiency and cytotoxicity
The transfection efficiency was investigated by flow cy-
tometry. Cells were seeded in 6-well plates at an initialFigure 2 Structure characterization of chitosan-g-PEI by FTIR spectra. The c
Their functional groups correspond to the representative bands on the FTIdensity of 4 × 105 cell well−1 and allowed to reach 70% to
80% confluence. Before transfection, cells were washed
with PBS and refreshed with antibiotic-free medium.
Then, the cells were treated with complexes containing
4 μg of pIRES2-ZsGreen1-hBMP2 plasmid and incubated
for 24 h. Chitosan (10 kDa) and PEI (25 kDa) were used
for comparison in gene delivery. Untreated cell was used as
the negative control. Before examination, cells were
refreshed with complete medium and cultured for another
24 h. The ZsGreen1 GFP expression was observed under a
fluorescence microscope and quantified by flow cytometry.
In vitro stem cell viability under transfection condition
was evaluated by MTT assay. Cells were seeded in 96-well
plates at an initial density of 1× 104 cells well−1 and cul-
tured in a 100-μL medium containing the complexes. The
procedure was similar to the course of transfection for
evaluating their cytotoxicity during transfection. The MTT
assay was performed according to the manufacturer’s in-
struction, and the results were shown as the percentage of
cell viability comparing with the control group. Each value
was averaged from six independent experiments.hemical structure of chitosan, chitosan-g-PEI, and PEI was shown (A).
R spectra (B).
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BMP2 gene was delivered to BMSC. After transfection,
the supernatant was collected for testing the BMP2 ex-
pression utilizing a commercially available ELISA kit
(PeproTech Inc., Rocky Hill, NJ, USA). The activation of
its downstream signaling pathway was investigated by
Western blot analysis. Cells were lysed in immunopre-
cipitation buffer (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1% TritonX-100, 0.5% sodium deoxycholate) con-
taining protease inhibitors. After centrifuge of the ly-
sates, the supernatants were separated by SDS-PAGE
and blotted onto a nitrocellulose membrane (Bio-Rad
Laboratories, Hercules, CA, USA). The proteins were
analyzed with anti-Smad1 and anti-phospho-Smad1/5/8
(Western blot) antibodies, and visualized by SuperSignal
West Femto Substrate system (Thermo).
Osteogenic differentiation
After transfection of BMP2 gene, BMSC were induced
for osteogenic differentiation in osteogenic medium.
Fourteen days after transfection, the alkaline phosphat-
ase activity (ALP) assay was performed. Cells were
rinsed with PBS and lysed in the buffer containing 0.1%
(v/v) Triton X-100, 1 mM MgCl2, and 20 mM Tris. The
freezing and thawing process was followed to disrupt the
cell membranes. Samples were incubated with ALPFigure 3 Characterization of chitosan-g-PEI and pIRES2-ZsGreen1-hBMP2 plasmi
ration by gel retardation (A), morphology observed by TEM (B), and particle sizesubstrate solution at 37°C for 30 min and then stopped
by 3 M NaOH. These were performed in 96-well micro-
plate with triplicate, and the assay was read against the
blank at 405 nm by microplate reader. The total protein
content was determined by BCA kit. Calcium deposit
was stained by Alizarin Red S staining and quantified at
around 21 days. Briefly, cells were washed with PBS and
fixed with 10% formalin for 30 min. Alizarin Red S stain-
ing working solution with pH value around 4.1 ~ 4.3 was
used to stain the cells. Thoroughly washed by distilled
water, the calcium deposit with the red color could be
observed under a microscope. Quantification of calcium
deposition was made by extracting Alizarin Red S stain-
ing with 10% cetylpyridinium chloride (CPC) and meas-
uring the absorbance at 570 nm.Statistical analysis
All the data presented are expressed as Mean ± SD and
the statistical analysis was made using ANOVA and a
multiple comparisons test. The difference was considered
statistically significant when p value was less than 0.05.Results and discussion
Chitosan-g-PEI has been demonstrated as a promising
gene carrier. In this study, it was applied to bone marrowd DNA complexes. The complexes were characterized by the critical complex
in histogram and zeta potential in line plot (C). Scale bar: 500 nm.
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chitosan- and PEI-mediated situation. The transfection ef-
ficiency, cytotoxicity, and the expression of delivered gene
were examined.
Characterization of the constructed pIRES2-ZsGreen1-hBMP2
plasmid
For conveniently observing the BMP2 expression, pIRES2-
ZsGreen1-hBMP2 dual expression plasmid was con-
structed containing both the functional gene of BMP2 and
the reporter gene of ZsGreen1 GFP as shown in Figure 1A.
To some extent, the ZsGreen1 GFP expression could indi-
cate the BMP2 expression level because BMP2 was earlier
translated than ZsGreen1 GFP according to this plasmid
translation sequence. The IRES element in the plasmid
makes sure the encoded proteins expressed separately.
Comparing with their fusion protein, this could avoid the
adverse interaction in their proteins’ function. The func-
tion of this constructed plasmid was examined by
ZsGreen1 GFP and BMP2 expression in COS-1 cells. TheFigure 4 Transfection efficiency of chitosan-g-PEI in bone marrow stem cells
adipogenic, and chondrogenic differentiation by Alizarin Red S, Oil Red O and
by gene carriers was visualized by fluorescence and quantified by flow cytomexpressed ZsGreen1 GFP was observed under fluorescence
microscopy as shown in Figure 1B. The insertion of BMP2
gene did not seem to affect the ZsGreen1 GFP expres-
sion comparing with the fluorescence images of pIRES2-
ZsGreen1 and pIRES2-hBMP2-ZsGreen1. BMP2 expres-
sion was examined by its gene expression using real-
time reverse transcription PCR (RT-PCR) as shown in
Figure 1C. Only pIRES2-hBMP2-ZsGreen1 group showed
the positive BMP2 mRNA expression. Both the control
group and the pIRES2-ZsGreen1 group showed the nega-
tive BMP2 mRNA expression. These results confirmed
the successful construction of the plasmid containing both
BMP2 and ZsGreen1 GFP for transfection investigation.
Structure comparison
The structure of chitosan-g-PEI, chitosan, and PEI was
compared by FTIR spectroscopy as shown in Figure 2.
In FTIR spectra, chitosan showed the representative
bands at 1,640 cm−1, 1,563 cm−1, and 1,077 cm−1, which
were attributed to C =O stretching (amide I band), N-H(BMSC). The extracted BMSC were capable of conducting the osteogenic,
toluidine blue staining (A). ZsGreen1 GFP expression in BMSC delivered
etry (B). Scale bar:100 μm.
Figure 5 Cell viability of the different complexes in bone marrow stem
cells. By MTT assay, chitosan and chitosan-g-PEI showed significant
higher cell viability than PEI.
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tion. PEI showed the characteristic peaks at 1,660 cm−1
for NH2 vibration and 1,139 cm−1 for C-N stretching.
Chitosan-g-PEI showed the increased signals at 1,660 cm−1
corresponding to the NH2 vibration of PEI. At the same
time, there were decreased signals at 1,563 cm−1 and
1,077 cm−1 attributed to the N-H deformation and C-O
stretching vibration of chitosan. Meanwhile, the appearance
of the signals at 910 cm−1 and 840 cm−1 corresponding to
the C-S stretching vibration were introduced by disulfide
linkage in chitosan-g-PEI.Characterization of chitosan-g-PEI/DNA complexes
Cationic polymers carrying the positive charge could com-
plex the negatively charged plasmid DNA through elec-
tronic interaction to form the nano-scaled particles for
cellular internalization and gene expression. The critical
complex ratio was investigated by gel electrophoresis.
Above the weight ratio of 1:1 (w:w), the migration of DNA
was completely retarded by chitosan-g-PEI.
The formed complexes exhibited as nano-particles
with a spherical shape and compacted structure as
shown in TEM image (Figure 3B). The particle size
and zeta potential of the complexed particles were in-
vestigated by static light scattering (SLS) as shown in
Figure 3C. Above the weight ratio of 0.5 when the
polymers could completely condense DNA, the sizes of
the complexes reduced to around 100 nm. At the same
time, the zeta potential rose to around 30 mV. Further
increasing the weight ratio, the excessive cationic poly-
mer contributed to the surface positive charge, which
is necessary for the complexes binding to anionic cell
surfaces for cellular internalization.Transfection efficiency and cytotoxicity of chitosan-g-PEI
on stem cells
Mesenchymal stem cells (MSCs) are undifferentiated
multipotent cells which reside in various human tissues
and have the potential to differentiate into osteoblasts,
chondrocytes, adipocytes, fibroblasts, and other tissues
of mesenchymal origin [39]. To assess the multilineage
differentiation capacity, the extracted bone marrow stem
cells underwent osteogenic, adipogenic, and chondro-
genic induction by different culture media. It could be
observed that these cells are capable of conducting the
osteogenic, adipogenic, and chondrogenic differentiation
visualized by Alizarin Red S, Oil Red O and toluidine
blue staining, respectively (Figure 4A).
pIRES2-ZsGreen1-hBMP2 plasmid was delivered to
BMSC by chitosan-g-PEI, chitosan, and PEI. ZsGreen1
GFP expression could indicate the BMP2-expressed
level. The results showed the obvious positive GFP ex-
pression in groups of chitosan-g-PEI and PEI as shown
in Figure 4B. The chitosan-mediated group showed a
low level of GFP expression, and the control group
showed the negative results. Analyzed by flow cytometry,
the rate of the positive GFP expression cells reached
17.2% and 14.6% for chitosan-g-PEI and PEI, respect-
ively. However, the chitosan-mediated group could only
reach 3.4%. All of these efficiencies were actually not
very high due to the difficulties in transfecting stem
cells [35]. It has been observed that most gene carriers work
effectively for immortal cells in culture but fail in transfect-
ing primary cells because of the cell type-dependent differ-
ences [40]. It has been reported that PEI showed a much
higher transfection level than any other nonviral vector in
mammalian cells [41]. Its superior transfection efficiency in
most cell types benefits from the ‘proton-sponge’ effect.
Chitosan-g-PEI with the component of PEI also got a
benefit in delivering BMP2 gene to stem cells.
The cytotoxicity of the complexes to BMSC was inves-
tigated by MTT assay. Chitosan and chitosan-g-PEI
showed significant higher cell viability than PEI as
shown in Figure 5. There is no significant cytotoxicity
found in the complexes of chitosan. The complexes of
chitosan-g-PEI could maintain more than 80% of cell
viability when its weight ratio reached 25:1. This result
indicated that the selected formula of chitosan-g-PEI
complexes with the weight ratio of 20:1 is safe for the
stem cells. In the case of PEI, the cells were barely alive
above the weight ratio of 5:1. The commonly used for-
mula of PEI complexes weight ratio of 2:1 has already
showed very toxic to the stem cells. Studies have found
that PEI could induce the rapid perturbation of the
plasma membrane with 30 min of exposure. Then, ‘mito-
chondrially mediated’ apoptotic program was activated
over the following 24 h [16]. This toxic was dose-
dependent and increased with the molecular weight.
Figure 6 BMP2 expression was examined by ELISA and Western blot assay. The expressed BMP2 protein was quantified by ELISA analysis (A), and
the activation of its downstream Smad1/5/8 signaling pathway was studied through Western blot assay (B).
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Chitosan-g-PEI with the component of low molecular
weight PEI and biocompatible chitosan showed accept-
able cell viability in stem cells.
BMP2 expression
The bone morphogenetic protein (BMP) signaling is re-
quired in endochondral ossification and bone formation.
BMPs are soluble transmembrane glycoproteins with
low molecular weight in normal bone, which belong to
the transforming growth factor beta (TGF-β) superfamily
[42]. To date, there are more than 20 BMPs members
with diverse effects on the growth and differentiation of
MSCs, as well as on their ability to synthesize matrix.
Among the BMP family, bone morphogenetic protein-2
(BMP2) is a well-known stimulus for bone regeneration
and has already been clinically used in the enhancement
of the lumbar spine fusion and the treatment of acute
tibia fractures. It has been demonstrated with the effect
in stimulating the commitment of MSC into osteoblast
lineage [43].
In delivering pIRES2-ZsGreen1-hBMP2 plasmid to
BMSC, ZsGreen1 GFP expression could be observed by
fluorescence as shown above. The expressed BMP2Figure 7 Osteogenic differentiation of the bone marrow stem cells. The osteo
(B) between different vector-mediated BMP2 gene transfections.protein was investigated by Elisa and Western blot.
Three days post-transfection, the secreted BMP2 protein
reached around 22 ng/mL in chitosan-g-PEI-mediated
group, which was significantly higher than other groups
(Figure 6A). The expressed BMP2 functions by activating
intracellular Smad proteins. The activated Smad protein
complex then regulates the expression of osteoblastic genes
by interacting with various transcription factors [44]. By
Western blot assay, the activated Smad1/5/8 in the form of
phosphorylation was enhanced post-transfection comparing
with the control group. The chitosan-g-PEI-mediated trans-
fection showed the significant enhancement in Smad1/5/8
phosphorylation as shown in Figure 6B. The activated
Smad complexes were then translocated into nucleus to
regulate the transcription of specific target genes. BMP2/
Smad signaling is a known mediator of Runx2 expression
in starting the osteogenesis [45].
Osteogenic differentiation of stem cells
Bone formation involves a complex sequence of events
including the recruitment, proliferation, and differenti-
ation of stem cell to osteoblast lineage [46]. BMP2 has
the effect in stimulating the commitment of MSC into
osteoblast lineage and promoting the maturation ofgenic differentiation was compared by ALP activity (A) and mineralization
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required to migrate to the injured site and differentiate
into osteoblasts to produce the bone matrix for repair
[47]. For ex vivo MSC transplantation, the genetically
modified cells with BMP2 gene showed an enhanced
repairing ability in large scaled bone defect [48]. These ap-
plications realized based on the effective transfection of
MSC by gene carriers.
BMP2 could induce BMSC to differentiate into osteo-
blast [49]. The osteogenic differentiation was investi-
gated through alkaline phosphatase activity (ALP) and
mineralization ability. ALP activity is an important early
osteoblastic differentiation marker. Fourteen days post-
transfection, the chitosan-g-PEI-mediated group showed
highest ALP activities (Figure 7A). PEI showed the
slightly lower effect comparing with chitosan-g-PEI, but
significant higher than chitosan and control. The similar
tendency could be observed in the cells mineralization.
Alizarin Red S staining is a common histochemical tech-
nique for detecting the calcium deposit in mineralized
tissues and cultures. It was conducted on 21 days post-
transfection for detecting the cell-mediated deposition of
extracellular calcium and phosphate salts. The enhance-
ment of osteogenesis could be observed on chitosan-g-
PEI- and PEI-mediated groups (Figure 7B). The quantifi-
cation of osteogenic differentiation was conducted by
extracting the staining using CPC solution to calculate
the calcium deposit. Based on these results, chitosan-g-
PEI-mediated BMP2 gene transfection showed a significant
stronger ability in inducing MSC osteogenic differentiation
than the chitosan and control groups, which is even higher
than that of PEI. The cytotoxicity of high molecular weight
PEI reduced the cell viability leading to the reduced func-
tion of expressed transgene.
Bone regeneration utilizing gene therapy either by dir-
ect (in vivo) or cell-mediated (ex vivo) procedure has
been extensively studied [50]. Although relatively safer
the less efficiency of nonviral vectors compared with viral
vectors is still the challenge for their application. Ectopic
bone formation could be obtained using adenoviruses and
adeno-associated virus (AAV) encoding for several BMP
genes by direct intramuscular injection [51-53]. For nonvi-
ral vector, gene-activated matrices (GAM) and ex vivo
procedure are usually used to improve the in vivo effect.
PEI-mediated BMP4 gene delivery incorporated in a poly
(lactic-co-glycolic acid) (PLGA) scaffold could enhance the
bone regeneration in a cranial critical-sized defect [54]. In
a comparison study, stem cells modified by liposome-
mediated BMP2 gene transfer was loaded in collagen
sponge for the healing of critical-sized defects in the rat
mandible. Although it took slightly longer time than the
adenoviral-mediated group, the mature bone matrix
could be observed in the central region of the defect
6 weeks after the operation [36]. The ex vivo genetherapy for the orthopedic-oriented approaches provides
the benefits of cellular component for fast and predict-
able bone formation. The novel technique of sonoporation
and electroporation could further enhance the efficiency
of nonviral vector-mediated gene delivery. Stem cell-based
BMP2 gene delivery utilizing nucleogection, a method
using electroporation for transfection, could induce ec-
topic bone formation 4 weeks after cell implantation [55].
Conclusions
Chitosan-g-PEI as nonviral vector was investigated on
its in vitro gene delivering effect in bone marrow stem
cells. pIRES2-ZsGreen1-hBMP2 dual expression plasmid
containing both the ZsGreen1 GFP reporter gene and
the BMP2 functional gene was constructed for monitor-
ing the transgene expression level. Chitosan-g-PEI-medi-
ated gene transfer showed 17.2% of transfection
efficiency and more than 80% of cell viability in stem
cells. These values are higher than the PEI-mediated
one. The expression of the delivered BMP2 gene in stem
cells enhanced the osteogenic differentiation. These re-
sults demonstrated that chitosan-g-PEI is capable of ap-
plying in delivering gene to stem cells and providing
potential applications in stem cell-based gene therapy.
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